KIT 1 (Keep in Touch) Project-Televisits for Cancer Patients during Italian Lockdown for COVID-19 Pandemic: The Real-World Experience of Establishing a Telemedicine System.

Publication date: Jul 06, 2023

To evaluate the adoption of an integrated eHealth platform for televisit/monitoring/consultation during the COVID-19 pandemic. During the lockdown imposed by the Italian government during the COVID19 pandemic spread, a dedicated multi-professional working group was set up in the Radiation Oncology Department with the primary aim of reducing patients’ exposure to COVID-19 by adopting de-centralized/remote consultation methodologies. Each patient’s clinical history was screened before the visit to assess if a traditional clinical visit would be recommended or if a remote evaluation was to be preferred. Real world data (RWD) in the form of patient-reported outcomes (PROMs) and patient reported experiences (PREMs) were collected from patients who underwent televisit/teleconsultation through the eHealth platform. During the lockdown period (from 8 March to 4 May 2020) a total of 1956 visits were managed. A total of 983 (50. 26%) of these visits were performed via email (to apply for and to upload of documents) and phone call management; 31 visits (1. 58%) were performed using the eHealth system. Substantially, all patients found the eHealth platform useful and user-friendly, consistently indicating that this type of service would also be useful after the pandemic. The rapid implementation of an eHealth system was feasible and well-accepted by the patients during the pandemic. However, we believe that further evidence is to be generated to further support large-scale adoption.

Open Access PDF

Concepts Keywords
Healthcare digital health
Italian radiation oncology
Pandemic telemedicine


Type Source Name
disease MESH Cancer
disease MESH COVID-19 Pandemic
disease IDO history
drug DRUGBANK Coenzyme M
drug DRUGBANK Etoperidone
disease VO time
drug DRUGBANK Trestolone
disease IDO contact tracing
disease VO organization
disease MESH infections
disease VO document
disease MESH emergency
disease IDO symptom
disease MESH morbidity
disease VO population
drug DRUGBANK Cysteamine
disease IDO infection
disease VO protocol
disease VO device
disease IDO blood
drug DRUGBANK Oxygen
disease VO volume
disease IDO facility
disease VO dose
drug DRUGBANK Methionine
disease IDO site
disease MESH death
disease IDO process
disease VO USA
drug DRUGBANK Fenamole
disease IDO intervention
drug DRUGBANK Alginic acid
drug DRUGBANK Fluocinolone acetonide
disease MESH Occupational burnout
disease MESH vulvar cancer
drug DRUGBANK Bismuth subgallate
disease MESH metastases
drug DRUGBANK Efavirenz
disease MESH pneumonia
disease MESH Influenza
disease MESH Hypertension
drug DRUGBANK Alprostadil
disease VO effectiveness
disease MESH Lung Cancer
disease MESH rectal cancer
disease MESH pancreatic cancer
pathway KEGG Pancreatic cancer
disease MESH maculopathy
disease MESH uveal melanoma
disease MESH glioblastoma
disease MESH Hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH endometrial cancer
pathway KEGG Endometrial cancer
disease MESH melanoma
pathway KEGG Melanoma
disease MESH skin cancers
disease MESH neck cancer
disease VO Iss

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *